SS
ALDX icon

SBI Securities’s Aldeyra Therapeutics ALDX Stock Holding History

SBI Securities’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03K Buy
1,423
+1,160
+441% +$1.99K ﹤0.01% 2401
2026
Q1 		$444 Hold
263
– – ﹤0.01% 2928
2025
Q4 		$1.36K Hold
263
– – ﹤0.01% 2528
2025
Q3 		$1.37K Hold
263
– – ﹤0.01% 2568
2025
Q2 		$1.01K Hold
263
– – ﹤0.01% 2676
2025
Q1 		$1.51K Buy
263
+11
+4% +$65 ﹤0.01% 2419
2024
Q4 		$1.26K Buy
+252
New +$1.29K ﹤0.01% 2504

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SBI Securities's ALDX Position: Q2 2026 in Review

SBI Securities increased its Aldeyra Therapeutics (ALDX) stake by 441% in Q2 2026, buying an estimated $1.99K and bringing the position to 1,423 shares worth $3.03K. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

SBI Securities first reported a position in ALDX in Q4 2024 and has held it in 7 quarters since. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • SBI Securities held 1,423 shares of Aldeyra Therapeutics worth $3.03K as of Q2 2026.
  • SBI Securities bought 1,160 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.99K.
  • Aldeyra Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2401 holding.
  • SBI Securities first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.